Irisin: a new molecular marker and target in metabolic disorder

Lipids in Health and Disease

Review

Yue-ye Huang¹  Shen Qu²  Jia-qi Chen²  Aaron M Gusdon³ 

[1] Department of Endocrinology and Metabolism, Shanghai 10th People’s Hospital, School of Medicine, Tongji University, 200072, Shanghai, China;Department of Endocrinology and Metabolism, Shanghai 10th People’s Hospital, School of Medicine, Tongji University, 200072, Shanghai, China;Nanjing Medical University, 210029, Nanjing, Jiangsu, China;Department of Neurology, Weill Cornell Medical College, 10065, New York, NY, USA;

关键词: Irisin;    Obesity;    Metabolic diseases;   

DOI  :  10.1186/1476-511X-14-2

 received in 2014-10-18, accepted in 2015-01-07,  发布年份 2015

来源: Springer

【 摘 要 】

Irisin is a newly discovered exercise-mediated myokine which regulates energy metabolism and has been the subject of much recent research. Irisin plays an important role in metabolic diseases making it a potential new target to combat obesity and its associated disorders, such as T2DM. However, the results of several recent studies investigating the effects of irisin have been controversial. The present review will introduce the discovery of irisin, the role of irisin in metabolic disorders, possible mechanisms, and unanswered questions for future research.

【 授权许可】

Unknown   
© Chen et al.; licensee BioMed Central. 2015. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.